EN DE
Watch Femasys Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Femasys Inc (FEMY) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Femasys Inc stock $1.36, price $1.50, that is 9.3% below the price, quality 27 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US31447E1055

FI Femasys Inc logo Thin data Nov 10, 2026

Femasys Inc

FEMY · US
Expensive, weak quality

Our calculation puts a fair price 9% below what the stock costs today.

Expensive Growth (revenue 5y +17.2 %/yr in USD)
Moderate debt
Insiders bought $134,000 (6M)
Revenue last quarter 19% below a year ago.
Fair value $1.36 · Overvalued
Quality 27/100
Negative free cash flow
Trails peers (1/8)
Narrow moat 9/100
Thin data
Estimate
Watch Femasys Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$160.40 $1.31 Fair Value $1.36 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $1.31 – $160.40 · fair‑value band $1.02 – $1.70 · the $1.50 price screens above the $1.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Femasys in your weekly email

Every Wednesday you see whether Femasys is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally.

Show moreShow less

The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.

It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations.

Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Stock analysis

Femasys Inc (FEMY) currently trades at $1.50, while our estimate is $1.36, 9% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.02 (bear) to $1.70 (bull), the price of $1.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Femasys Inc reported revenue of $2.3M in FY2025 versus $1.2M in FY2021, a compound +18.1%/yr. Reported net income was −$18.6M in FY2025.

Key figures

Market cap $13.1M Micro · P/S ratio 5.14 · EPS (TTM) $−3.28 · Return on equity −425% · Return on assets (EBIT) −75.6% (5-year average) · Operating margin −1,527% · Revenue (TTM) $2.3M · Revenue growth (YoY) −18.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 93% below its 52-week high and 15% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −42% fair-value upside, at −9%, FEMY screens cheaper than that median.

Fair Value

Bear $1.02 Fair Value $1.36 Bull $1.70
Price $1.50 · Downside -9.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 69
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 40
Debt, balance sheet and risk of trouble
Investment 55
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 2
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 5 officers or directors bought shares worth $134,000, most recently on Aug 7, 2026. Buying cluster

  • BuyKathy Lee-SepsickChief Executive Officer, Director15,625 shares at $3.20$50,000Aug 7, 2026
  • BuyDov ElefantChief Financial Officer15,625 shares at $3.20$50,000Aug 7, 2026
  • BuyJohn Charles CanningChief Operating Officer4,375 shares at $3.20$14,000Aug 7, 2026
  • BuyJeremy Alexander SiposChief Technology Officer3,125 shares at $3.20$10,000Aug 7, 2026
  • BuyJeffrey Gerald MifekChief Clinical-Medical Affairs3,125 shares at $3.20$10,000Aug 7, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+40.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−668.0% (2020) → −767.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

FEMY screens overvalued: fair value 9% below the price. Compare with Intuitive Surgical, Inc →

Compare Femasys Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 197 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −9.3% · Above median
Profitability
Return on assets −89.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −18.9% · Bottom 25%
Balance sheet
Debt / equity 0.54× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 2.23× · Pricier than median
P/S (12 months) 5.69× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)21 · sector 18
FUTURE (revenue growth)0 · sector 39
PAST (return on equity)0 · sector 26
HEALTH (low debt)73 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $88.62 $131.27 +48% vs FEMY
EssilorLuxottica Société anonyme EL €182.55 €196.22 +7% vs FEMY
Intuitive Surgical, Inc ISRG $449.53 $353.90 −21% vs FEMY
Medline Inc MDLN $42.16 $28.59 −32% vs FEMY
Alcon Inc ALC CHF 59.48 CHF 34.29 −42% vs FEMY
Becton, Dickinson and Company BDX $214.52 $97.80 −54% vs FEMY
Straumann Holding STMN CHF 106.65 CHF 45.50 −57% vs FEMY
West Pharmaceutical Services, Inc WST $412.86 $139.22 −66% vs FEMY
Sartorius Stedim Biotech S.A DIM €226.80 €54.82 −76% vs FEMY
Sartorius Aktiengesellschaft SRT €229.00 €42.50 −81% vs FEMY

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Femasys Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Femasys Inc Fair Value". https://www.fairvalue-calculator.com/stock/FEMY

Frequently asked questions

Is Femasys Inc (FEMY) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $1.36 versus a price of $1.50, about 9% lower (overvalued).
What is the fair value of FEMY?
Our estimate for Femasys Inc is $1.36 (as of Nov 10, 2026), built from audited fundamentals. The current price: $1.50.
What is the quality score of FEMY?
Femasys Inc has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Femasys Inc (FEMY)?
Our calculated price target is the estimate of $1.36 (as of Nov 10, 2026). Cautious scenario $1.02, optimistic scenario $1.70. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Femasys Inc stock forecast for 2026?
Our estimate puts fair value at $1.36, about 9% lower versus a price of $1.50 (overvalued). Cautious scenario $1.02, optimistic scenario $1.70. The calculation is refreshed regularly with new filings.
What is the revenue of Femasys Inc (FEMY)?
Femasys Inc reported trailing-twelve-month revenue of about $2.3M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Femasys Inc (FEMY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Femasys Inc it is $1.36 per share (as of Nov 10, 2026), against a price of $1.50.
Is Femasys Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, FEMY trades above its calculated fair value: price $1.50, fair value $1.36, a gap of about −9% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FEMY?
No. The price is what the market pays today ($1.50); the fair value is what the company's own numbers justify ($1.36). For Femasys Inc the two are $0.1400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Femasys Inc worth?
The market values Femasys Inc at about $13.1M (market capitalisation, as of Nov 10, 2026). Per share that is $1.50; our models calculate a fair value of $1.36 per share.
What do the bullish and bearish scenarios say about FEMY?
Our models span a range for Femasys Inc: cautious scenario $1.02, base $1.36, optimistic $1.70 per share (as of Nov 10, 2026, price $1.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Femasys Inc (FEMY)?
Balance-sheet figures for Femasys Inc (as of Nov 10, 2026): return on equity −425.0%, debt of 0.54 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is FEMY from its 52-week high?
Femasys Inc trades at $1.50, about 93% below its 52-week high of $20.20 and 15% above the low of $1.31 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of $1.36 is for.
Which stocks are comparable to Femasys Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Femasys Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $1.50, calculated fair value $1.36 (−9%), Quality Score 27/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Femasys Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Femasys Inc (FEMY)?
The closing price on Nov 11, 2026 was $1.50. Our estimate is $1.36, about 9% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Femasys Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Femasys Inc

How large is the market capitalisation of Femasys Inc (FEMY)?
The market capitalisation of Femasys Inc is $13.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Femasys Inc (FEMY)?
The price-to-sales ratio of Femasys Inc is 5.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Femasys Inc (FEMY)?
Earnings per share at Femasys Inc are $−3.28. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Femasys Inc (FEMY)?
The return on equity (ROE) of Femasys Inc is −425% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Femasys Inc (FEMY)?
On an EBIT basis the return on assets of Femasys Inc is −75.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Femasys Inc (FEMY)?
The operating margin of Femasys Inc is −1,527% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Femasys Inc (FEMY)?
Revenue at Femasys Inc is growing −18.9% versus a year earlier (3y avg +23.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Femasys Inc (FEMY) generate?
The free cash flow of Femasys Inc is −$19.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Femasys Inc (FEMY) hold?
Femasys Inc holds more cash than debt, $4.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Femasys Inc in the live analysis

One click puts Femasys Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.